Abemaciclib
Abemaciclib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Anatomic Stage III Breast Cancer AJCC v8、Anatomic Stage IV Breast Cancer AJCC v8、Locally Advanced Unresectable HER2-Negative Breast Carcinoma、Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
2 项
已进入 III/IV 期
15 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- University of Washington
- Jose Pablo Leone
- University of Texas Southwestern Medical Center
- Mayo Clinic
- Novartis Pharmaceuticals
- National Cancer Institute (NCI)
- QuantumLeap Healthcare Collaborative
- H. Lee Moffitt Cancer Center and Research Institute
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、英国、法国、中国、Greece、德国、瑞士、比利时、意大利、South Korea、西班牙、Turkey (Türkiye)
正在招募患者的 Abemaciclib 研究
ETHAN - ET for Male BC
II 期招募中美国NCT05501704Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
II 期招募中美国NCT04614194DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
不适用招募中美国NCT06388122Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.
不适用招募中英国NCT07243002Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
I 期招募中美国NCT05372640I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases
I 期 / II 期招募中美国NCT04923542Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
不适用招募中美国NCT07214532A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
II 期招募中美国NCT07112053Immunomonitoring of Breast Cancer Patients During Systemic Treatment
不适用招募中法国NCT04925856Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
II 期招募中美国NCT04040205A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
I 期招募中美国NCT06678269Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
III 期招募中中国NCT06341621Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
II 期招募中美国NCT05524584Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
不适用招募中GreeceNCT04985058Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea
不适用招募中中国NCT07264998Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
II 期招募中中国NCT07180160Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
II 期招募中德国NCT06207734Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
IV 期招募中德国瑞士NCT05362760Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
II 期招募中美国NCT07340541Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
I 期 / II 期招募中美国比利时法国德国NCT05386108Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
不适用招募中中国NCT07180056First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
I 期 / II 期招募中美国比利时法国德国NCT05768139INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
II 期招募中美国NCT02977780
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。